Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients
Liver International · 2026-04 · 46 (4)
DOI: 10.1111/liv.70559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 26.02.2026. Verfasst von Habiba Kamal und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Alanine Transaminase, Coinfection, Hepatitis B, Chronic, Hepatitis D, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment‐naïve patients with CHD. This study analysed the pattern and determinants of ALT elevation in a large cohort of patients with CHD, including young adults, compared to propensity score‐matched (PSM) patients with chronic hepatitis B (CHB).
Methods
We identified 2382 treatment‐naïve HBsAg+ adults with CHD (HDV RNA positive) and 1553 with CHB attending a liver center in Mongolia during 2015–2023. The correlation between ALT levels, virological, biochemical, and fibrosis parameters was assessed using Spearman coefficient (rho). Logistic regression analysis was used to identify determinants of elevated ALT in 1371 PSM pairs with CHD and CHB matched on age, sex, metabolic factors, and date of initial test.
Results
In CHD, 78.5% of patients had ALT elevation, with the highest prevalence in the 18–20 years group ( n = 219, 84.5%). This age group displayed 8.2‐adjusted odds ratio (aOR) for elevated ALT, 2.7‐aOR for elevated GGT, and 4.5‐aOR of cirrhosis than matched CHB group (all p < 0.05). In CHD, ALT correlated weakly with HDV RNA (rho = 0.23) and liver stiffness (rho = 0.37), moderately with GGT (rho = 0.48), while showed no correlation with HBV DNA or HBsAg. Independent factors for elevated ALT were age < 30 years, elevated GGT and HDV RNA levels.
Conclusions
In this large cohort of Asian patients, an earlier and more severe inflammatory process could be demonstrated in CHD compared to CHB regardless of liver cirrhosis. Longitudinal studies are warranted to risk‐stratify and prioritise patients for therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
- The Liver Center, Ulaanbaatar, Mongolia.
- ONOM Foundation, Ulaanbaatar, Mongolia.
- Unit of Hepatology, Department of Upper GI Diseases, Karolinska University Hospital, Stockholm, Sweden.
- Cytel Statistical Consultancy, Stockholm, Sweden.
ORCID-Profile: Habiba Kamal, Soo Aleman
Zitieren
APA
Kamal, H., Jargalsaikhan, G., Enkhtaivan, S., Lindahl, K., Hagström, H., Bruce, D., Ingre, M., Dashtserenx, B., Lkhagva-Ochir, O., Ulziibadrakh, T., Bungert, A., Wedemeyer, H., Dashdorj, N. B., & Aleman, S. (2026). Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients. Liver International, 46(4). https://doi.org/10.1111/liv.70559
Vancouver
Kamal H, Jargalsaikhan G, Enkhtaivan S, Lindahl K, Hagström H, Bruce D, et al. Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients. Liver International. 2026;46(4). doi:10.1111/liv.70559
BibTeX
@article{Kamal2026,
author = {Kamal, Habiba and Jargalsaikhan, Ganbolor and Enkhtaivan, Sanjaasuren and Lindahl, Karin and Hagström, Hannes and Bruce, Daniel and Ingre, Michael and Dashtserenx, Bekhbold and Lkhagva-Ochir, Oyungerel and Ulziibadrakh, Tuvshinjargal and Bungert, Andreas and Wedemeyer, Heiner and Dashdorj, Naranjargal B and Aleman, Soo},
title = {Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients},
journal = {Liver International},
year = {2026},
volume = {46},
number = {4},
doi = {10.1111/liv.70559}
}
EUVIMED